James Dunn is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
909 9th Ave
Suite 300
Fort Worth, TX 761043903
Telephone
817-336-7191Registry record last updated 14 Aug 2015.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20241 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20231 payment
- Dexcom, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.2%Insulin Analog8%Tresiba Flextouch U-20038%Toujeo Solostar27%Tresiba Flextouch U-10021%Fiasp Flextouch14%Part D<11 patientsProton pump inhibitor6.4%Pantoprazole Sodium45%Omeprazole39%Dexlansoprazole Dr16%Part D<11 patients+ 7 more classes in this area
Cardiovascular
29.1%Beta blocker6.6%Metoprolol Tartrate37%Metoprolol Succinate34%Carvedilol30%Part D<11 patientsStatin5.8%Atorvastatin Calcium79%Rosuvastatin Calcium21%Part D<11 patients+ 6 more classes in this area
Respiratory
8.5%Phenothiazine3.1%Promethazine Hcl100%Part D<11 patientsLeukotriene Receptor Antagonist3%Montelukast Sodium100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1985–1990 per NIH RePORTER. The latest:
- CHARACTERIZATION OF A HUMAN OSTEOCLAST-LIKE CELL LINE
University of Texas Hlth Sci Ctr San Ant
FY1987R01AR035627
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”